Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
- PMID: 32674727
- DOI: 10.2174/0929867327666200716113136
Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Abstract
Peroxisome proliferator-activated receptor (PPAR), a ligand dependant transcription factor, is a member of the nuclear receptor superfamily. PPAR exists in three isoforms i.e. PPAR alpha (PPARα), PPAR beta (PPARβ), and PPAR gamma (PPARγ). These are multi-functional transcription factors and help in regulating inflammation, type 2 diabetes, lipid concentration in the body, metastasis, and tumor growth or angiogenesis. Activation of PPARγ causes inhibition of growth of cultured human breast, gastric, lung, prostate, and other cancer cells. PPARγ is mainly involved in fatty acid storage, glucose metabolism, and homeostasis and adipogenesis regulation. A large number of natural and synthetic ligands bind to PPARγ and modulate its activity. Ligands such as thiazolidinedione, troglitazone, rosiglitazone, pioglitazone effectively bind to PPARγ; however, most of these were found to display severe side effects such as hepatotoxicity, weight gain, cardiovascular complications and bladder tumor. Now the focus is shifted towards the development of dual-acting or pan PPAR ligands. The current review article describes the functions and role of PPARγ in various disease states. In addition, recently reported PPARγ ligands and pan PPAR ligands were discussed in detail. It is envisaged that the present review article may help in the development of potent PPAR ligands with no or minimal side effects.
Keywords: PPAR gamma; bladder tumor; cancer; diabetes; pan PPAR ligands; proliferator-activated receptor.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
PPAR dual agonists: are they opening Pandora's Box?Pharmacol Res. 2007 Aug;56(2):91-8. doi: 10.1016/j.phrs.2007.03.002. Epub 2007 Mar 14. Pharmacol Res. 2007. PMID: 17428674 Review.
-
G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.J Biol Chem. 2015 Aug 7;290(32):19544-57. doi: 10.1074/jbc.M115.638924. Epub 2015 Jun 23. J Biol Chem. 2015. PMID: 26105050 Free PMC article.
-
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.Vascul Pharmacol. 2006 Jul;45(1):19-28. doi: 10.1016/j.vph.2005.11.014. Epub 2006 Jun 16. Vascul Pharmacol. 2006. PMID: 16782410 Review.
-
Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.Curr Top Med Chem. 2008;8(17):1483-507. doi: 10.2174/156802608786413474. Curr Top Med Chem. 2008. PMID: 19075761 Review.
-
Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.Mol Pharmacol. 2009 Aug;76(2):414-24. doi: 10.1124/mol.109.056010. Epub 2009 May 29. Mol Pharmacol. 2009. PMID: 19483106
Cited by
-
In silico analysis of the antidiabetic terpenoid acankoreagenin binding to PPARγ.In Silico Pharmacol. 2021 Apr 15;9(1):32. doi: 10.1007/s40203-021-00091-0. eCollection 2021. In Silico Pharmacol. 2021. PMID: 33936928 Free PMC article.
-
Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor γ transactivation.Front Endocrinol (Lausanne). 2023 Jun 2;14:1156952. doi: 10.3389/fendo.2023.1156952. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37334286 Free PMC article.
-
Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp.Cancers (Basel). 2023 Jun 15;15(12):3199. doi: 10.3390/cancers15123199. Cancers (Basel). 2023. PMID: 37370809 Free PMC article. Review.
-
Integrated investigation and experimental validation of PPARG as an oncogenic driver: implications for prognostic assessment and therapeutic targeting in hepatocellular carcinoma.Front Pharmacol. 2023 Nov 15;14:1298341. doi: 10.3389/fphar.2023.1298341. eCollection 2023. Front Pharmacol. 2023. PMID: 38044948 Free PMC article.
-
Arrhythmogenic cardiomyopathy as a myogenic disease: highlights from cardiomyocytes derived from human induced pluripotent stem cells.Front Physiol. 2023 May 11;14:1191965. doi: 10.3389/fphys.2023.1191965. eCollection 2023. Front Physiol. 2023. PMID: 37250123 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical